11/18
07:00 am
mnmd
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
High
Report
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
11/14
07:49 am
mnmd
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions [Yahoo! Finance]
Low
Report
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions [Yahoo! Finance]
11/13
07:00 am
mnmd
MindMed to Participate in Upcoming Investor Conferences
Low
Report
MindMed to Participate in Upcoming Investor Conferences
11/11
08:10 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Low
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
11/8
06:19 am
mnmd
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... [Yahoo! Finance]
High
Report
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... [Yahoo! Finance]
11/7
04:01 pm
mnmd
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
Medium
Report
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
10/24
07:00 am
mnmd
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
Low
Report
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
10/15
07:48 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/14
09:02 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.
Medium
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.
9/16
10:55 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
9/9
04:01 pm
mnmd
MindMed Announces New Employee Inducement Grants
Low
Report
MindMed Announces New Employee Inducement Grants
9/4
07:00 am
mnmd
MindMed to Participate in September Investor Conferences
Medium
Report
MindMed to Participate in September Investor Conferences
8/29
08:42 am
mnmd
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target raised by analysts at HC Wainwright from $35.00 to $55.00. They now have a "buy" rating on the stock.
Low
Report
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target raised by analysts at HC Wainwright from $35.00 to $55.00. They now have a "buy" rating on the stock.
8/23
07:52 pm
mnmd
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report [Seeking Alpha]
Low
Report
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report [Seeking Alpha]